Rimonabant – a new group of metabolic drugs?

Ida Kinalska; Katarzyna Siewko

eISSN: 2084-9877
ISSN: 1896-9666

Przegląd Kardiodiabetologiczny/Cardio-Diabetological Review

Current issue Archive About the journal Abstracting and indexing Contact Instructions for authors

3/2007
vol. 2

Send email

Copy url:

abstract:

Rimonabant – a new group of metabolic drugs?

Ida Kinalska

,

Katarzyna Siewko

Przegląd Kardiodiabetologiczny 2007; 2, 3: 197–202

Online publish date: 2007/10/01

View full text Get citation

Type 2 diabetes mellitus is assotiated with obesity and multiple cardiometabolic risk factors. Improvement in glycemia is often associated with weight gain. Oral antidiabetic agents that can achieve HbA1c reductions plus weight loss and imorovemrnts in aterogenic dyslipidemia. Rimonabant, a selective cannabinoid type 1 CB1 blocker, regulates centrally and peripherally the endigenous overactivity of the endocannabinoid system, promoting reductions in body weight, waist cimcumference and atrogenic dyslipidemia.

keywords:

Rimonabant – a new group of metabolic drugs?

Ida Kinalska , Katarzyna Siewko

rimonabant, obesity

Ida Kinalska

,

Katarzyna Siewko